Quick Facts
FONT-SIZE Plus   Neg
Share SHARE
mail  E-MAIL

Vanda Pharma Acquires Rights To NK-1 Receptor Antagonist From Eli Lilly

RELATED NEWS
Trade VNDA now with 
4/16/2012 7:08 AM ET

Vanda Pharmaceuticals Inc. (VNDA: Quote) said it has acquired an exclusive world-wide license from Eli Lilly and Co. (LLY: Quote) to develop and commercialize a small molecule neurokinin 1 receptor, or NK-1R, antagonist for all human indications.

As per the terms of the agreement with Eli Lilly, Vanda Pharma will pay an initial license fee of $1 million and will be responsible for all development costs. Eli Lilly is also eligible to get extra payments on the basis of achievement of specified development and commercialization milestones as well as tiered-royalties on net sales at percentage rates up to the low double digits. These milestones include $4 million for pre-NDA approval milestones and up to $95 million for future regulatory approval and sales milestones.

Vanda Pharma stated that in 2012, it plans to initiate and complete the technology transfer activities and further examine the clinical and commercial profile of VLY-686. This strategic evaluation will further inform potential indications for an early development clinical program, noted the company.

Click here to receive FREE breaking news email alerts for VANDA PHARMACEUTICALS and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Growth in Philadelphia-area manufacturing activity has accelerated by much more than anticipated in the month of April, according to the results of the Federal Reserve Bank of Philadelphia's Business Outlook Survey released on Thursday. The Philly Fed said its diffusion index of current activity climbed to 16.6 in April from 9.0 in March, with a positive reading indicating growth. After moving notably higher over the past few sessions, stocks are turning in a lackluster performance in morning trading on Thursday. The major averages have been showing modest moves, holding close to the unchanged line. After reporting initial jobless claims at their lowest level in almost seven years in the previous week, the Labor Department released a report on Thursday showing that claims rebounded slightly in the week ended April 12th. The Labor Department said initial jobless claims inched up to 304,000, an increase of 2,000 from the previous week's revised level of 302,000.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.